{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:03:32Z","timestamp":1770509012092,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental and Molecular Pathology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.yexmp.2010.06.011","type":"journal-article","created":{"date-parts":[[2010,7,12]],"date-time":"2010-07-12T00:47:23Z","timestamp":1278895643000},"page":"175-181","source":"Crossref","is-referenced-by-count":25,"title":["Expression and prognostic relevance of MAGE-C1\/CT7 and MAGE-C2\/CT10 in osteolytic lesions of patients with multiple myeloma"],"prefix":"10.1016","volume":"89","author":[{"given":"Caroline","family":"Pabst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jozef","family":"Zustin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Luetkens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djordje","family":"Atanackovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 12","key":"10.1016\/j.yexmp.2010.06.011_bb0005","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ijc.22718","article-title":"Multiple myeloma: a review of the epidemiologic literature","volume":"120","author":"Alexander","year":"2007","journal-title":"Int. J. Cancer"},{"issue":"Database issue","key":"10.1016\/j.yexmp.2010.06.011_bb0010","doi-asserted-by":"crossref","first-page":"D816","DOI":"10.1093\/nar\/gkn673","article-title":"CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens","volume":"37","author":"Almeida","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0015","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood-2006-04-014480","article-title":"Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation","volume":"109","author":"Atanackovic","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.yexmp.2010.06.011_bb0020","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2009.014464","article-title":"Cancer-testis antigens MAGE-C1\/CT7 and MAGE-A3 promote the survival of multiple myeloma cells","volume":"95","author":"Atanackovic","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.yexmp.2010.06.011_bb0025","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1158\/1078-0432.CCR-08-0989","article-title":"Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma","volume":"15","author":"Atanackovic","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0030","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/CCO.0b013e3283136984","article-title":"Advances in therapy of multiple myeloma","volume":"20","author":"Blade","year":"2008","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0035","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.4049\/jimmunol.178.5.3307","article-title":"Cancer\/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis","volume":"178","author":"Condomines","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0040","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/leu.2008.43","article-title":"MAGE-C1\/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma","volume":"22","author":"Curioni-Fontecedro","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.yexmp.2010.06.011_bb0045","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2141.2008.07421.x","article-title":"Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992\u20132004","volume":"144","author":"Dores","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0050","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V57.2.333.333","article-title":"The growth fraction of human myeloma cells","volume":"57","author":"Drewinko","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.yexmp.2010.06.011_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0037-1963(01)90087-3","article-title":"The epidemiology of multiple myeloma","volume":"38","author":"Durie","year":"2001","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0060","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1084\/jem.179.3.921","article-title":"Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes","volume":"179","author":"Gaugler","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0065","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0070","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study","volume":"91","author":"Harousseau","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.yexmp.2010.06.011_bb0075","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1634\/theoncologist.2008-0077","article-title":"Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy","volume":"13","author":"Hazarika","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.yexmp.2010.06.011_bb0080","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/jjco\/hyn113","article-title":"Comparison of time trends in multiple myeloma incidence (1973\u20131997) in East Asia, Europe and United States, from Cancer Incidence in Five Continents, Vols IV\u2013VIII","volume":"38","author":"Hirabayashi","year":"2008","journal-title":"Jpn J. Clin. Oncol."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0085","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1186\/bcr2249","article-title":"Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer","volume":"11","author":"Jacquemier","year":"2009","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0090","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/ijc.10416","article-title":"CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues","volume":"99","author":"Jungbluth","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexmp.2010.06.011_bb0095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2004-12-4931","article-title":"The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3\/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation","volume":"106","author":"Jungbluth","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.yexmp.2010.06.011_bb0100","first-page":"15","article-title":"Expression of cancer-testis (CT) antigens in placenta","volume":"7","author":"Jungbluth","year":"2007","journal-title":"Cancer Immun."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0105","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/modpathol.2009.167","article-title":"The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer","volume":"23","author":"Klintman","year":"2010","journal-title":"Mod Pathol."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0115","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.4065\/82.10.1179","article-title":"Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma","volume":"82","author":"Lacy","year":"2007","journal-title":"Mayo Clin. Proc."},{"issue":"15","key":"10.1016\/j.yexmp.2010.06.011_bb0120","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide-dexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.yexmp.2010.06.011_bb0125","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2141.2006.06484.x","article-title":"Cancer-testis antigens in haematological malignancies","volume":"136","author":"Meklat","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0130","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","article-title":"Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA\u2013Italian Multiple Myeloma Network","volume":"25","author":"Palumbo","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0135","first-page":"204","article-title":"KI67 proliferation index in tumors of the upper urinary tract as related to established prognostic factors and long-term survival","volume":"51","author":"Rey","year":"1998","journal-title":"Arch. Esp. Urol."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0140","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/BF02303480","article-title":"Prognostic value of cell proliferation (Ki-67 antigen) and nuclear DNA content in clinically resectable, distal bile duct carcinoma","volume":"5","author":"Rijken","year":"1998","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0145","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0150","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1034\/j.1600-065X.2002.18803.x","article-title":"Cancer\/testis antigens: an expanding family of targets for cancer immunotherapy","volume":"188","author":"Scanlan","year":"2002","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0155","first-page":"1","article-title":"The cancer\/testis genes: review, standardization, and commentary","volume":"4","author":"Scanlan","year":"2004","journal-title":"Cancer Immun."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0160","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/hon.757","article-title":"Prognostic impact of cytogenetic aberrations in patients with multiple myeloma or monoclonal gammopathy of unknown significance","volume":"23","author":"Schilling","year":"2005","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0165","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cancergencyto.2005.10.016","article-title":"Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance","volume":"167","author":"Schmidt-Wolf","year":"2006","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0170","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","article-title":"The Ki-67 protein: from the known and the unknown","volume":"182","author":"Scholzen","year":"2000","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0175","first-page":"257","article-title":"Tissue microarrays","volume":"114","author":"Simon","year":"2005","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0180","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1349-7006.2008.00738.x","article-title":"MAGE-C1\/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome","volume":"99","author":"Tinguely","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.yexmp.2010.06.011_bb0185","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.ejca.2005.11.035","article-title":"Myeloma bone disease and treatment options","volume":"42","author":"Yeh","year":"2006","journal-title":"Eur. J. Cancer"}],"container-title":["Experimental and Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448001000095X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448001000095X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T21:08:12Z","timestamp":1591477692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448001000095X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S001448001000095X"],"URL":"https:\/\/doi.org\/10.1016\/j.yexmp.2010.06.011","relation":{},"ISSN":["0014-4800"],"issn-type":[{"value":"0014-4800","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}